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40 E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3Background: Meningiomas are usually benign tumors and cyto-
genetically well-characterized. Most tumors show either mono-
somy 22 or a diploid karyotype. Progression of meningiomas is
correlated with increasing hypodiploidy and the loss of the short
arm of chromosome 1. The aim of this study was to assess intra-
tumoral patterns of clonal chromosomal evolution in order to
identify tumor progression pathways and to analyze their correla-
tion with time to recurrence.
Methods: From 1973 to 2004, 661 patients with complete tumor
resections and cytogenetic characterization were followed up.
We have developed oncogenetic trees mixture models for esti-
mating the most likely order of cytogenetic aberrations.
Results: Overall, in 8.0% (53/661) of the tumors at least one
recurrence was documented during the study. Our results
showed a significant correlation between cytogenetic data and
recurrence (p < 0.001), location (p < 105) and WHO grade
(p < 1015). The estimated model was used to assign a genetic
progression score (GPS). The GPS of a tumor is a quantitative
measure and allows precise assessment of genetic progression.
We classified tumors in three groups with low genetic progres-
sion (GPS < 2), intermediate genetic progression (2 6 GPS < 6)
and advanced genetic progression (GPSP 6). The recurrence rate
is 7.9% (27/343) in the low progression group, 4.0% (11/273) in the
medium progression group, and 33.3% (15/45) in the high pro-
gression group.
Conclusion: Therefore, cytogenetic classification of meningio-
mas is a powerful tool to predict tumor recurrence and a valuable
parameter for the postoperative management protocol.
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Background: S100 proteins comprise a family of calcium-modu-
lated proteins that have recently been associated with epithelial
tumours.
Methods: We examined the expression of two members of this
family, S100A8 and S100A9 in human prostate adenocarcinomas
by means of histochemical staining procedures. S100A9 was
additionally analysed in patient serum using ELISA. Furthermore,
the function of the two proteins was investigated in prostate
derived cell lines using expression constructs and recombinant
proteins.
Results: S100A8 and S100A9 were upregulated in prostatic intra-
epithelial neoplasia and preferentially in high-grade adenocarci-
nomas, whereas benign tissue was negative or showed weak
expression of the proteins. Moreover, the analysis of S100A9 inpatient serum revealed significantly elevated S100A9 serum levels
in cancer patients compared to BPH (benign prostatic hyperplasia)
patients or healthy individuals.1
In cell culture experiments S100A8 and S100A9 were identified
as extracellular factors which induce MAP kinase and NF-jB sig-
nalling pathways and stimulate the migration of prostate epithe-
lial cells.2
Conclusion: The data show that S100A8 and S100A9 are linked to
the activation of important features of prostate cancer cells. Fur-
thermore, S100A8 and S100A9 represent novel markers for pros-
tate cancer, which may prove useful for future diagnostic and/
or therapeutic approaches.
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Background: Upregulation of polyamine transporters on the sur-
face of tumor cells and the internalisation of biogenic polyamines
by active transport processes may be exploited for the accumula-
tion of millimolar quantities of reporter molecules.
Methods: Novel intracellular contrast agents for magnetic reso-
nance imaging with high tumor uptake have been developed,
based on Gd(III)-DOTA. Uptake of these agents into cultured
tumor cell lines B16 (mouse melanoma), MH3924A (Morris hepa-
toma), A493 (kidney carinoma) and 3T3 NIH (mouse fibroblasts)
was quantitated by ICP-MS. Furthermore fluorescence tagged
polyamines were evaluated as optical imaging agents using con-
focal laser scanning microscopy to investigate uptake into B16
and MH3924A tumor cells.
Results: At 10 lM incubation with Gd(III)-DOTA-polyamine con-
jugates for 1 h, an uptake of 0.02–0.23 fmol/cell was achieved, cor-
responding to intracellular concentrations of 11–110 lM Gd. The
cell uptake increased in the order A493 (0.02 fmol/cell) < 3T3NIH
(0.03 fmol/cell) < B16 (0.05 fmol/cell) < MH3924A (0.23 fmol/cell).
0.017–0.17 fmol/cell internalized Gd is needed to achieve a detect-
able contrast enhancement via T1-weighted MRI. Evidence for
intracellular uptake of the fluorophore labeled polyamines in
MH3924A and B16 tumor cells, investigated by confocal lase scan-
ning microscopy, resulted in comparable uptake values as com-
pared to the Gd(III)-DOTA derivatives. Initial in vivo studies
showed that fluorophore labeled polyamines can be imaged in
the tumor.
Conclusions: This study illustrates the potential of polyamine
transporters which are upregulated in proliferating cells can be
used for contrast agent enhanced MRI and optical imaging of
tumors.
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